

CHAPTER 7: REFERENCES

Almond S, Knapp M, Francois C, et al. (2004). Relapse in Schizophrenia: costs, clinical outcomes and quality of life. *Br J Psychiatry*. 184:346-351.

American Psychiatric Association. (1997). Practice Guideline for the treatment of patients with Schizophrenia. *Am J Psychiatry*. 154:4-52.

American Psychiatric Association. (2002). Diagnostic and Statistical Manual of Mental Disorders –DSM-IV-TR. Fourth Edition - Text Revision, Washington D.C. pp 297-317.

Barnard EJ, Gagiano CA, Joubert G. (1998). Patients with chronic mental illness attending outpatient groups – factors influencing relapse. *S Afr Med J*. 88:752-758.

Bebbington P, Wilkins S, Jones P, et al. (1993). Life events and psychosis: initial results from the Camberwell Collaborative Psychosis Study. *Br J Psychiatry*. 162:72-79.

Birchwood M, Smith J, MacMillan F, et al. (1989). Predicting Relapse in Schizophrenia: The development and implementation of an early signs monitoring system using patients and families as Observers, a preliminary investigation. *Psychol Med*. 19:649-656.

Birchwood M, Mason R, Macmillan F, et al. (1993). Depression, demoralization and control over psychotic illness: a comparison of depressed and non-depressed patients with a chronic psychosis. *Psychol Med*. 23:387-395.

Bloch S, Hafner J, Harari E, et al. (1994). The family in clinical psychiatry. Oxford University Press. pp 109-131.

Brauteseth LT. (1992). Demographic considerations of african (black) schizophrenic patients presenting at Baragwanath hospital psychiatry outpatients and inpatients facilities. University of the Witwatersand, Johannesburg. Med Thesis, WM 203 BRA.

Buchanan A. (1992). A two-year prospective study of treatment compliance in patients with schizophrenia. *Psychol Med*. 22:787-797.

Carr VJ, Lewin TJ, Neil AJ, et al. (2004). Premorbid, psychosocial and clinical predictors of the costs of schizophrenia and other psychoses. *Br J Psychiatry*. 184:517-525.

Carpenter WT. (1996). Maintenance Therapy of Persons with Schizophrenia. *J Clin Psychiatry*. 57:10-16.

Cohen LJ, Test MA, Brown RL. (1990). Suicide and Schizophrenia: Data from a prospective community treatment study. *Am J Psychiatry*. 147:602-607.

Crow TJ, McMillan JF, Johnson AL, et al. (1986). The Northwick Park study of first episode of schizophrenia: II. A randomised controlled trial of prophylactic neuroleptic treatment. *Br J Psychiatry*. 148:120-127.

DiMatteo MR, DiNicola DD. (1982). Achieving patient compliance. The psychology of the medical practitioner's. Pergamon Press. pp 1-28.

Dixon L, Haas G, Weiden P, et al. (1990). Acute effects of drug abuse in schizophrenic patients: clinical observations and patients self-reports. *Schizophr Bull*. 16:69-79.

Docherty JP, Van Kammen DP, Siris SG, et al. (1978). Stages of onset of schizophrenic psychosis. *Am J Psychiatry* 135:420-426.

Du Prezz RR, Griffith WC, Page M. (2005). Major depressive disorder as a co-morbid diagnosis in schizophrenia versus the diagnosis of schizoaffective disorder-depressed type. *S Afr Psychiatry Rev*. 8:134-139.

Drake RE, Osher FC, Wallach MA, et al. (1989). Alcohol use and abuse in schizophrenia. A prospective community study. *J Nerv Ment Dis*. 177:408-414.

Dunbar J. (1979). Issues in Assessment. In Cohen SJ - New directions in patient compliance. Lexington Books. pp 41-57.

Emsley RA, Roos L, Tsjabelala J, et al. (2006). Schizophrenia Foundation. Science in Africa pp 1-3. In www.scienceinafrica.co.za/sfound.htm

- Fenton SW, McGlashan TH, Victor BJ, et al. (1997). Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders. *Am J Psychiatry*. 154:199-204.
- Fenton SW, Blyler CR, Heinssen RK. (1997). Determinants of medication compliance in schizophrenia: Empirical and clinical findings. *Schizophrenia Bulletin*. 4:637-651.
- Fleishhacker WW, Melse U, Gunther V, et al. (1994). Compliance with antipsychotic drug treatment: influence of side-effects. *Acta Psychiatr Scand*. 89:11-1.
- Gelder MG, Lopez-Ibor JJ, Andreasen NC. (2000). *New Oxford textbook of psychiatry*. Oxford University Press. pp 567-636.
- Gift TE, Strauss JS, Kokes RF, et al. (1980). Schizophrenia: Affect and outcome. *Am J Psychiatry* 137: 580-585.
- Gillis LS, Koch A, Joyi M. (1989). Improving compliance in Xhosa psychiatric patients. *SAMJ*. 76: 205-208.
- Gillis LS, Sandler R, Jakoet A, et al. (1986). Readmissions to a psychiatric hospital: Outcome on follow-up. *SAMJ*. 70; 735-739.
- Government Gazette (2002). *Mental Health Care Act 2002*. Republic of South Africa, Government Gazette, Cape Town: Act No.17, 6 November, Vol 449.
- Gupta S, Hendricks S, Kenkel, et al. (1996). Relapse in schizophrenia: Is there a relationship to substance abuse? *Schizophrenia Research*. 20:153-156.
- Haywood TW, Kravitz HM, Grossman LS, et al. (1995). Predicting the "revolving door" phenomenon among patients with schizophrenia, schizoaffective, and affective disorders. *Am J Psychiatry*. 152:856-861.
- Heila H, Isometsa ET, Henriksson MM, et al. (1997). Suicide and schizophrenia: a nationwide Psychological autopsy study on age- and sex-specific clinical characteristics of 92 suicide victims with schizophrenia. *Am J Psychiatry*. 154:1235-1242.

Heinrichs DW, Cohen BP, Carpenter WT. (1985). Early insight and the management of schizophrenic decompensation. *J Nerv Ment Dis.* 173:133-138.

Hirsch SR, Jolley AG (1989). The dysphoric syndrome in schizophrenia and its implications for relapse. *Br J Psychiatry.* 155:46-50.

Hirsch S, Bowen J, Emami J, et al. (1996). A One Year prospective Study of the effect of life events and medication in the Aetiology of Schizophrenic relapse. *Br J Psychiatry.* 168:49-56.

Hogarty GE, Ulrich RF. (1998). The limitations of anti-psychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. *J Psych Research.* 32:243-250.

Hudson TJ, Owen RR, Trush CR, et al. (2004). A pilot study of barriers to medication adherence in schizophrenia. *J Clin Psychiatry.* 65:211-216.

Hunter PE, Storat B. (1994). Psychosocial triggers of relapse in persons with chronic mental illness: A pilot study. *Mental Health Nursing.* 15:67-72.

Johnson DAW. (1988). The significance of depression in the prediction of relapse in chronic schizophrenia. *Br J Psychiatry.* 152:320-323.

Joubert PM. (2002). Community psychiatry in South Africa. *SA Psych Review.* 5:4-6.

Kane JM. (1990). Management Strategies for the Treatment of Schizophrenia. *J Clin Psychiatry.* 60:13-17.

Kavanagh DJ. (1992). Recent developments in expressed emotion in schizophrenia. *Br J Psychiatry.* 160:601-620.

Knapp M, Marks I, Wolstenholme, et al. (1998). Home-based versus hospital-based care for serious mental illness. *Br J Psychiatry.* 172:506-512.

Knights A, Hirsch SR. (1981). 'Revealed' depression and drug treatment for schizophrenia. *Arch Gen Psychiatry,* 38:806-811.

Knudson P, Vilmar T. (1984). Cannabis and neuroleptic agents in schizophrenia. *Acta Psychiatr Scand.* 69:162-174.

Kovaszny B, Fleischer J, Tanenberg-Karant M, et al. (1997). Substance use disorder and early course of illness in schizophrenia and affective psychosis. *Schizophrenia bulletin.* 23:195-201.

Kozuki Y, Froelicher ES. (2003). Lack of awareness and nonadherence in schizophrenia. *Western journal of nursing research.* 25:57-74.

Leff JP, Vaugan C. (1981). The role of maintenance therapy and relatives' expressed emotion in relapse of schizophrenia: A two-year follow-up. *Br J Psychiatry* 139:102-104.

Leff JP, Kuipers L, Berkowitz R, et al. (1985). A controlled trial of interventions in the families of schizophrenic patients: Two-year follow-up. *Br J Psychiatry.* 146:594-600.

Linszen DH, Dingemans PM, Lenior ME. (1994). Cannabis abuse and the course of recent-onset schizophrenic disorder. *Arch Gen Psychiatry.* 51: 273-279.

Malla AK, Cortese L, Shaw TS, et al. (1990). Life events and relapse: A one year prospective study. *Soc. Psychiatry Psychiatry Epidemiol.* 25:221-224.

Marder SR. (2003). Overview of Partial Compliance. *J Clin Psychiatry.* 64:3-9.

Marvin IH, Steven Lamberty J, Jim Mintz, et al. (2000). A Program for Relapse Prevention in Schizophrenia: A controlled study. *Arch Gen Psychiatry.* 57:277-283.

McEvoy JP, Apperson J, Appelbaum PS, et al. (1989). Insight in Schizophrenia, Its relationship to acute psychopathology. *J Nerv Ment Dis.* 177:43-47.

McEvoy JP, Freter S, Everett G, et al. (1989). Insight and the Clinical outcome of schizophrenic patients. *J Nerv Ment Dis.* 177:48-51.

Murray RM, Castle DJ. (2000). Genetic and environmental risk factors for schizophrenia. In *Oxford Textbook of Psychiatry.* Ed. MG Gelder. Oxford University press. Pp: 599-605.

- Mwaba K, Molamu RB. (1998). Perceived causes of relapse among a sample of recovering patients at a Mafikeng Hospital. *Curationis*. 21:55-57.
- Negrette JC, Knapp WP, Douglas DE, et al. (1986). Cannabis affects the severity of schizophrenic symptoms: Results of a clinical survey. *Psychol Med*. 16:515-520.
- Nelson AA, Gold BH, Huchinson RA, et al. (1975). Drug default among schizophrenic patients. *Am J Psychiatry*. 32:1237-1242.
- Ohmori T, Ito K, Abekawa T, et al. (1999). Psychotic relapse and maintenance therapy in paranoid schizophrenia: A 15 year follow up. *Eur Arch Psychiatry Clin Neurosci*. 249:73-78.
- Olfson M, Mechanic D, Hansell S, et al. (2000). Predicting medication non compliance after hospital discharge among patients with schizophrenia. *Psychiat Serv*. 51:215-222.
- Peralta V, Cuesta MJ. (1992). Influence of cannabis abuse on schizophrenic psychopathology. *Acta Psychiatr Scand*. 85:127-130.
- Perkins DO. (2002). Predictors of Noncompliance in Patients with Schizophrenia. *J Clin Psychiatry*. 63:12-16.
- Piggot TA, Carson WH, Saha AR, et al. (2003). Aripiprazole for the prevention of relapse in Stabilized Patients with Chronic Schizophrenia: A placebo-controlled 26-Week Study. *J Clin Psychiatry*. 64:1048-1057.
- Pourmand DD, Kavanagh DJ, Vaughan K. (2005). Expressed emotion as predictor of relapse in patients with comorbid psychoses and substance use disorder. *Australian and New Zealand Journal of Psychiatry*. 39:473-478.
- Razali MS, Yahya H. (1995). Compliance with treatment in schizophrenia. A drug intervention program in a developing program. *Acta Psychiatr Scandinav*. 91:331-335.
- Regier DA, Farmer ME, Rae DS. (1990). Comorbidity of mental disorders with alcohol and other drug abuses. *J Am Med Ass*. 264:2511-2518.

Robertson B, Allwood CW, Gagiano C. (2001). Textbook of Psychiatry for Southern Africa. Oxford University Press. pp 417-428.

Robinson D, Woerner MG, Ma J. et al. (1999). Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 56:241-247.

Roy A, Thompson R, Kennedy S. (1983). Depression in chronic schizophrenia. Br J Psychiatry. 142:465-470.

Sadock BJ, Sadock VA. (2000). Kaplan & Sadock's Comprehensive Textbook of Psychiatry, seven edition. Published by Lippincott, Williams & Wilkins. pp 1196-1199.

Sadock BJ, Sadock VA. (2003). Synopsis of Psychiatry, Behavioral sciences/ Clinical psychiatry. Lippincott, Williams & Wilkins. pp 471-504.

Salloum IM, Moss HB, Daley DC. (1991). Substance abuse and schizophrenia: impediments to optimal care. Am J Drug Alcohol Abuse. 17:321-336.

Schneier FR, Siris SG. (1987). A review of psychoactive substance use and abuse in schizophrenia: Patterns of drug choice. J Nerv Ment Dis. 175: 641-652.

Siris SG. (2000). Depression in Schizophrenia: Perspective in the Era of "Atypical" antipsychotic agents. Am J Psychiatry. 157:1379-1389.

Solombela PW, Uys LR. (1994). Factors influencing the relapse of outpatients with schizophrenia in the Kentani area of Transkei. Curationis. 17:24-28.

Sullivan G, Wells KB, Morgenstern H, et al. (1995). Identifying modifiable risk factors for rehospitalization: A case control study of seriously mentally ill persons in Mississippi. Am J Psychiatry. 152:1749-1752.

Suzuki Y, Yasumura S, Fukao S, et al. (2003). Associated factors of rehospitalization among schizophrenic patients. Psychiatry and Clinical Neurosciences. 57:555-561.

Swofford CD, Kasckow JW, Scheller-Gilkey G, et al. (1996). Substance use: a powerful predictor of relapse in schizophrenia. Schizophrenia Research. 20:145-151

Thieda P, Beard S, Ritchter A, et al. (2003). An Economic Review of Compliance with medication therapy in the Treatment of Schizophrenia. *Psychiat serv.* 54:508-516.

Tollefson GD, Sanger TM, Lu Y, et al. (1998). Depressive signs and symptoms in schizophrenia. A prospective blinded trial of olanzapine and haloperidol. *Arch Gen psychiatry.* 55:250-258.

Warner R, Taylor D, Wright J, et al. (1994). Substance use among the mentally: prevalence, reasons for use, and effects on illness. *Am J Orthopsychiatry.* 64:30-39.

Weiden P, Glazer W. (1997). Assessment and treatment selection for "revolving door" inpatients with schizophrenia. *Psychiatric Quarterly.* 68:377-393.

World Health Organization. (2004). Neuroscience of psychoactive substance use and dependence. World Health Organization, Geneva. pp 170-180

World Health Organization. (2003). Adherence to long-term therapies, evidence for action. World Health Organization, Geneva. pp 3-45.

Wright P, Stern J, Phelan M. (2005). *Core Psychiatry.* Elsevier Saunders. 2nd edition. pp 147-151.